General Partner Inc’s AstraZeneca AZN Stock Holding History

General Partner Inc’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$62K	Hold	384	–	–	0.03%	127
2026 Q2	$72.8K	Hold	384	–	–	0.04%	124
2026 Q1	$75.7K	Hold	384	–	–	0.05%	117
2025 Q4	$70.6K	Hold	384	–	–	0.04%	118
2025 Q3	$58.9K	Hold	384	–	–	0.03%	127
2025 Q2	$53.7K	Hold	384	–	–	0.03%	128
2025 Q1	$56.4K	Hold	384	–	–	0.04%	122
2024 Q4	$50.3K	Hold	384	–	–	0.03%	126
2024 Q3	$59.8K	Hold	384	–	–	0.04%	118
2024 Q2	$59.9K	Hold	384	–	–	0.04%	114
2024 Q1	$52K	Buy	+384	New	+$50.8K	0.03%	127

Other funds holding AZN

Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Border to Coast Pensions Partnership Leeds, United Kingdom $7.27B AUM 24.98% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $10.1B AUM 30.4% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

ZWJ Investment Counsel Atlanta, Georgia $3.24B AUM 31.6% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return

General Partner Inc's AZN Position: Q3 2026 in Review

General Partner Inc held its AstraZeneca (AZN) position steady in Q3 2026 at 384 shares worth $62K. The position accounts for 0.03% of the portfolio, ranked #127.

General Partner Inc first reported a position in AZN in Q1 2024 and has held it in 11 quarters since. The position peaked at $75.7K in Q1 2026. 380 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

General Partner Inc held 384 shares of AstraZeneca worth $62K as of Q3 2026.
General Partner Inc left its AstraZeneca share count unchanged in Q3 2026.
AstraZeneca made up 0.03% of General Partner Inc's portfolio in Q3 2026, its #127 holding.
General Partner Inc first reported a position in AstraZeneca in Q1 2024 and has held it in 11 quarters since.
General Partner Inc's AstraZeneca position peaked at $75.7K in Q1 2026.
380 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on General Partner Inc's 13F filing for Q3 2026, filed 5 Oct 2026.